CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria
The purpose of this study was to investigate the potential impact of CYP3A4, CYP3A5, and CYP3A7 polymorphisms on the concentration and efficacy of tacrolimus in a cohort of pediatric patients with nephrotic range proteinuria.
Genetic variants including CYP3A5*3 (rs776746), CYP3A4*1G (rs2242480), rs4646437, and CYP3A7 rs2257401 and rs10211 were detected in 70 pediatric patients with nephrotic range proteinuria. The relationships of dose-adjusted trough concentration (C0) of tacrolimus with corresponding genotypes were investigated.
The tacrolimus concentration in patients without CYP3A5*3 A allele was 94% higher than those with A allele (90.7 vs 54.2, P = 0.00006). The CYP3A7 rs2257401 was also associated with the concentration of tacrolimus. The C allele carriers had an obviously lower C0 than the non-carriers (62.4 vs 90.7, P = 0.001). In addition, there were significant differences in tacrolimus concentration among CYP3A7 rs10211 G carriers and non-carriers; the latter had an almost twofold C0 of the former (101.8 vs 59.6, P = 0.0004).
Our study demonstrated the associations between CYP3A5*3, CYP3A7 rs2257401 and rs10211, and tacrolimus concentration in pediatric patients with nephrotic range proteinuria. Children with CYP3A5*3 A, CYP3A7 rs2257401 C, and rs10211 G alleles might need a higher dose of tacrolimus.
KeywordsCYP3A5 CYP3A7 Polymorphisms Tacrolimus Pediatric patients Nephrotic range proteinuria
Hongxia Liu and Qinxia Xu contributed equally to this article. Xiaoyan Qiu and Huajun Sun conceived the study. Xiaoyan Qiu, Qinxia Xu, and Hongxia Liu participated in the research design. Hongxia Liu, Xinyu Kuang, Wenyan Huang, and Qi Zhao contributed to the acquisition of the patients’ data. Zhihu Jiang and Zhiling Li performed the CYP3A5*3 genotyping. Qinxia Xu performed the research and analyzed the data. Xiaoyan Qiu and Qinxia Xu drafted. All the authors revised the manuscript.
Hongxia Liu had financial support from the Shanghai Municipal Commission of Health and Family Planning (No. 20164Y0122). Dr. Xiaoyan Qiu had support from the Shanghai “Rising Stars of Medical Talent” Youth Development Program-Clinical Pharmacist Program, National Natural Science Foundation of China (No. 81302854), and Natural Science Foundation of Shanghai (No. 13ZR1405200).
Compliance with ethical standards
The study was performed in accordance with the Declaration of Helsinki and its amendments. Protocols were approved by the Ethics Committee of Shanghai Children’s Hospital and written informed consents were obtained from all subjects.
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with animals performed by any of the authors.
- 1.Tang JT, Andrews LM, van Gelder T, Shi YY, van Schaik RH, Wang LL, Hesselink DA (2016) Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin Drug Metab Toxicol 12(5):555–565. https://doi.org/10.1517/17425255.2016.1170808 CrossRefPubMedGoogle Scholar
- 3.Li S, Yang H, Guo P, Ao X, Wan J, Li Q, Tan L (2017) Efficacy and safety of immunosuppressive medications for steroid-resistant nephrotic syndrome in children: a systematic review and network meta-analysis. Oncotarget 8(42):73050–73062. https://doi.org/10.18632/oncotarget.20377 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Yang EM, Lee ST, Choi HJ, Cho HY, Lee JH, Kang HG, Park YS, Cheong HI, Ha IS (2016) Tacrolimus for children with refractory nephrotic syndrome: a one-year prospective, multicenter, and open-label study of Tacrobell(R), a generic formula. World J Pediatr 12(1):60–65. https://doi.org/10.1007/s12519-015-0062-y CrossRefPubMedGoogle Scholar
- 18.Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383–391. https://doi.org/10.1038/86882 CrossRefPubMedGoogle Scholar
- 19.Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, Kurose K, Sai K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Hanai S, Nakajima T, Matsumoto K, Saito H, Goto Y, Kimura H, Katoh M, Sugai K, Minami N, Shirao K, Tamura T, Yamamoto N, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada J (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 23(1):100. https://doi.org/10.1002/humu.9210 CrossRefPubMedGoogle Scholar
- 20.Diekstra MH, Belaustegui A, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, Garcia-Donas J, Rodriguez-Antona C, Rini BI, Guchelaar HJ (2017) Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. Pharmacogenomics J 17(1):42–46. https://doi.org/10.1038/tpj.2015.100 CrossRefPubMedGoogle Scholar
- 21.Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Tangen CM, Chu L, Parnes HL, Schenk JM, Reichardt JK, Thompson IM, Figg WD (2015) Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. PLoS One 10(5):e0126672. https://doi.org/10.1371/journal.pone.0126672 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Li CJ, Li L, Lin L, Jiang HX, Zhong ZY, Li WM, Zhang YJ, Zheng P, Tan XH, Zhou L (2014) Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. PLoS One 9(1):e86206. https://doi.org/10.1371/journal.pone.0086206 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Sohn M, Kim MG, Han N, Kim IW, Gim J, Min SI, Song EY, Kim YS, Jung HS, Shin YK, Ha J, Oh JM (2018) Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients. Sci Rep 8(1):18064. https://doi.org/10.1038/s41598-018-36085-w CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Burk O, Tegude H, Koch I, Hustert E, Wolbold R, Glaeser H, Klein K, Fromm MF, Nuessler AK, Neuhaus P, Zanger UM, Eichelbaum M, Wojnowski L (2002) Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 277(27):24280–24288. https://doi.org/10.1074/jbc.M202345200 CrossRefPubMedGoogle Scholar
- 27.Knox B, Wang Y, Rogers LJ, Xuan J, Yu D, Guan H, Chen J, Shi T, Ning B, Kadlubar SA (2018) A functional SNP in the 3′-UTR of TAP2 gene interacts with microRNA hsa-miR-1270 to suppress the gene expression. Environ Mol Mutagen 59(2):134–143. https://doi.org/10.1002/em.22159 CrossRefPubMedGoogle Scholar
- 28.Wei R, Yang F, Urban TJ, Li L, Chalasani N, Flockhart DA, Liu W (2012) Impact of the interaction between 3′-UTR SNPs and microRNA on the expression of human xenobiotic metabolism enzyme and transporter genes. Front Genet 3:248. https://doi.org/10.3389/fgene.2012.00248 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Zong YP, Wang ZJ, Zhou WL, Zhou WM, Ma TL, Huang ZK, Zhao CC, Xu Z, Tan RY, Gu M (2017) Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies. World J Pediatr 13(5):421–426. https://doi.org/10.1007/s12519-017-0035-4 CrossRefPubMedGoogle Scholar
- 31.Asempa TE, Rebellato LM, Hudson S, Briley K, Maldonado AQ (2018) Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients. Clin Transpl 32(1). https://doi.org/10.1111/ctr.13162
- 32.Qu L, Lu Y, Ying M, Li B, Weng C, Xie Z, Liang L, Lin C, Yang X, Feng S, Wang Y, Shen X, Zhou Q, Chen Y, Chen Z, Wu J, Lin W, Shen Y, Qin J, Xu H, Xu F, Wang J, Chen J, Jiang H, Huang H (2017) Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients. Oncotarget 8(46):81285–81294. https://doi.org/10.18632/oncotarget.18150 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Rojas L, Neumann I, Herrero MJ, Boso V, Reig J, Poveda JL, Megias J, Bea S, Alino SF (2015) Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J 15(1):38–48. https://doi.org/10.1038/tpj.2014.38 CrossRefPubMedGoogle Scholar
- 34.Buendia JA, Bramuglia G, Staatz CE (2014) Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis. Ther Drug Monit 36(4):442–447. https://doi.org/10.1097/FTD.0000000000000032 CrossRefPubMedGoogle Scholar
- 35.Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S, Asberg A, Christensen H (2014) The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol 70(6):685–693. https://doi.org/10.1007/s00228-014-1656-3 CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, Deng CH, Xi LY, Cheng K, Ming YZ, Yang GP, Pei Q, Zhu LJ, Yuan H, Liao HQ, Ding JJ, Wu D, Zhou YN, Jing NN, Huang ZJ (2013) Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics 23(5):251–261. https://doi.org/10.1097/FPC.0b013e32835fcbb6 CrossRefPubMedGoogle Scholar